Thomas N. Chase

Biography

Thomas N. Chase, MD, co-founder of Chase Pharmaceuticals and Chief Scientific Officer, served as the company’s first President and Chief Executive Officer. He is a globally recognized thought leader in neurodegenerative disorders and their treatment, with a focus on the pathogenesis and treatment of Alzheimer’s disease, Parkinson’s disease and related disorders. Dr. Chase is the former Scientific Director and head of the Experimental Therapeutics Branch for the National Institute of Neurological Disorders and Stroke (NINDS). He received his MD from Yale University School of Medicine. Dr. Chase completed his neurology residency at Harvard Medical School and Mass General Hospital and his postdoctoral training in basic and clinical neuropharmacology at the National Institute of Mental Health. He has served as principal investigator on nearly 200 clinical trials, authored numerous patents and published over 500 peer-reviewed papers. Dr. Chase was the founding president of the American Society for Experimental NeuroTherapeutics (ASENT). 

Research Interest

Chase Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders, including Alzheimer’s disease. The company’s development programs have the potential to profoundly improve the symptomatic treatment of Alzheimer's disease.